IGF-1 Rate-of-Change Interpretation: What Your Trend Means More Than a Single Number

IGF-1 (insulin-like growth factor 1) is a blood biomarker produced mainly by the liver in response to growth hormone signaling. It is not itself a drug. It is measured to gauge growth hormone axis activity, whether that axis is being treated with an FDA-approved GH replacement regimen, an FDA-approved GHRH analog such as tesamorelin (brand name Egrifta SV, approved specifically for HIV-associated lipodystrophy), or an off-label GH secretagogue peptide such as sermorelin, CJC-1295, ipamorelin, or the oral ghrelin mimetic MK-677 (ibutamoren). Immunoassay and LC-MS/MS platforms report different absolute numbers for the same blood sample, which matters for everything below.

The core claim of this page: two people with an identical IGF-1 reading can be in opposite clinical situations, one rising from a low baseline on a secretagogue peptide and gaining ground, the other falling from a supraphysiological peak after a dose was already reduced. The Endocrine Society's adult GH deficiency guideline addresses this indirectly by recommending IGF-1 rechecks 1 to 2 months after any dose change and every 6 months once stable, which only makes sense if the intervening trend, not a single draw, is what drives the next decision (Molitch et al., 2011).

Why does the trend matter more than one number?

A snapshot IGF-1 has real limits. A value of 180 ng/mL could belong to someone rising from a baseline of 90 ng/mL on a secretagogue peptide, or to someone falling from 310 ng/mL after a dose reduction. The number alone carries no direction, no velocity, and no information about safety margin.

Serial measurement converts a static marker into a dynamic one. Guideline-level monitoring for adult GH deficiency treats the trajectory, not a single absolute value, as the thing that should change management (Molitch et al., 2011). That guidance applies to an FDA-approved indication (confirmed adult GH deficiency); its cadence is applied by clinical analogy, not by direct approval, when peptides are used off-label for longevity or body-composition goals.

Establish a personal baseline before starting anything

IGF-1 has a genetically and lifestyle-influenced individual setpoint. A well-nourished 35-year-old man might run near 220 ng/mL with no intervention; a 55-year-old man might run near 110 ng/mL from age-related decline in GH pulse amplitude. Starting a peptide from 110 ng/mL is a different risk environment than starting from 220 ng/mL.

Before any GH-axis intervention, a reasonable practice is to collect at least one fasting morning IGF-1, and ideally two draws 2 to 4 weeks apart at the same lab on the same assay, then average them as the working baseline. This matters because IGF-1 has meaningful intra-individual variability across repeat draws, on the order of roughly 10 to 15% depending on the assay platform (Bidlingmaier et al., 2014).

What counts as a real rise versus noise

Given that variability, a change under roughly 20 ng/mL between draws falls close to assay and biological noise and should not be acted on without a confirmatory draw. A rise into the age-adjusted reference range from below it, or a rise clearly above the assay's own reported variability, is a more defensible signal of a real pharmacologic effect. A rise of 100 ng/mL or more within 8 weeks is not automatically unsafe, but it compresses the margin between a therapeutic effect and supraphysiological exposure and deserves a sooner-than-scheduled recheck.

What is a normal IGF-1, and does it change with age?

IGF-1 declines with age. Age-stratified reference intervals differ somewhat between labs and platforms; the table below is representative of one commonly used immunoassay-based normative dataset and should be read as illustrative rather than universal.

Different labs publish different intervals because they use different assay platforms. This is why comparing results across labs, or across immunoassay and LC-MS/MS, can manufacture the appearance of a change that is really a methodology artifact (Freda et al., 2014).

Sex and hormone-route effects

Premenopausal women tend to run somewhat lower IGF-1 than age-matched men, though the ranges overlap substantially (Janssen & Lamberts, 2003). Oral estrogen suppresses hepatic IGF-1 production through a first-pass effect on GH receptor signaling in the liver, while transdermal estradiol largely avoids that suppression; a study comparing routes found meaningfully different IGF-1 and GH-binding protein effects between oral and transdermal estrogen in postmenopausal women (Weissberger et al., 1991). Clinicians should ask about estrogen route before attributing an IGF-1 change to a peptide dose.

Testosterone appears to modestly enhance GH-driven IGF-1 production; a randomized trial of GH and testosterone in older men found combined effects worth distinguishing from either hormone alone (Giannoulis et al., 2006). Men who add a GH secretagogue peptide on top of stable TRT may see a larger IGF-1 response than either agent alone would produce, which argues for closer monitoring during that transition.

Assay platform is not a small detail

Head-to-head comparisons have found LC-MS/MS platforms reporting IGF-1 roughly 10 to 20% lower than immunoassay platforms, likely because immunoassays can cross-react with IGF binding protein fragments (Freda et al., 2014). No single reference preparation has been universally adopted across labs. Practically: if a patient's prior labs used one assay type and a new provider switches platforms, an apparent drop or rise may be entirely methodological rather than physiological.

How fast should IGF-1 move on a GH peptide, and when is that too fast?

GH secretagogue peptides fall into two off-label pharmacological classes: GHRH analogs (sermorelin, CJC-1295) and GHRP/ghrelin mimetics (ipamorelin, MK-677). Tesamorelin is the one FDA-approved GHRH analog, approved specifically for HIV-associated lipodystrophy, not for general longevity or body-composition use.

GHRH analogs amplify endogenous GH pulses, and the IGF-1 response is typically gradual, plateauing over roughly 6 to 10 weeks. Pooled data from tesamorelin's placebo-controlled phase 3 program in HIV-associated lipodystrophy demonstrated a clear IGF-1 increase during active treatment (Falutz et al., 2010). Readers should treat any specific week-by-week rate figure for sermorelin or CJC-1295 quoted elsewhere as needing verification against a primary trial report; the commentary literature on sermorelin available for this draft does not itself report a verified per-week slope, and that specific number has been removed here rather than repeated without support.

GHRPs and ghrelin mimetics tend to produce a faster initial rise, sometimes measurable by 4 weeks with a plateau by 8 to 12 weeks. Because MK-677 provides continuous rather than pulsatile receptor stimulation, it can raise IGF-1 more aggressively than injectable, pulsatile peptides at an equivalent degree of GH-axis stimulation, and earlier trial work found it reversed diet-induced catabolic changes in a study of older adults (Murphy et al., 1998). Some trials of GH secretagogues, including MK-677, have also reported adverse effects on glucose metabolism; readers should not treat any single percentage figure for IGF-1 rise or glucose change on MK-677 as confirmed unless it can be checked against the specific trial being cited, since study details (sample size, duration, exact effect size) vary across the MK-677 literature and were not fully verifiable from the sources available for this draft.

A rate-of-change decision framework

This is a general decision framework built from Endocrine Society monitoring cadence and the assay-variability literature above, applied by analogy to off-label GH peptide use. It is not a substitute for individualized clinical judgment, and it does not replace a clinician's dosing decision.

Step 1, baseline. Two fasting morning IGF-1 draws, same lab, same assay, 2 to 4 weeks apart. Average the results. Note the age-adjusted percentile.

Step 2, first on-therapy draw (commonly around week 8). Calculate delta-IGF-1 from the baseline average.

• Delta under roughly 20 ng/mL: within likely assay noise, or a true non-response. Before increasing dose, rule out poor adherence, low protein intake, undiagnosed hypothyroidism, or insulin resistance, since any of these can blunt the expected rise.
• Delta roughly 20 to 50 ng/mL, with the resulting value inside the age-adjusted range: a plausible therapeutic response. Continue the current dose and re-test on schedule.
• Delta roughly 50 to 100 ng/mL: a response is present. If the resulting value is still within the age-adjusted range, continue with monitoring at the next interval. If it is above range, discuss dose reduction with the prescribing clinician.
• Delta over roughly 100 ng/mL, or an absolute value above roughly 300 ng/mL: this is the point to pause and recheck sooner than scheduled, generally within 4 weeks, and to look for confounders (assay change, estrogen route change, illness, recent diet change) before resuming or adjusting the dose.

Step 3, maintenance. Once stable at a goal dose, a quarterly-to-semiannual recheck is reasonable, consistent with the cadence guideline bodies use for approved GH replacement (Molitch et al., 2011; Yuen et al., 2019).

This framework is a starting point for a conversation with a prescribing clinician, not a self-directed dosing protocol. Any dose change should be made by the clinician managing the therapy.

Is there an "optimal" IGF-1 for longevity, or is that overreach?

The phrase "optimal IGF-1" generates more opinion than settled data. What is better supported is a U-shaped risk pattern rather than a single optimal point.

A systematic review and meta-regression of prospective studies found that higher IGF-1 was associated with increased risk for several cancers, a finding widely cited as evidence against maximizing IGF-1 (Renehan et al., 2004). At the other end, population studies of IGF-1 decline across the adult lifespan describe how the fall in IGF-1 with age tracks with markers of aging and frailty risk (Maggio et al., 2006). Separately, studies of exceptional human longevity have found lower-than-expected IGF-1 in some long-lived cohorts, which has been used to argue that low IGF-1 itself promotes longevity (Milman et al., 2014).

That last finding is correlational, drawn from small, unusual populations, and confounded by body composition and metabolic factors specific to those cohorts. It should not be read as evidence that deliberately lowering IGF-1 extends life in a general adult population. Extrapolating findings from invertebrate longevity-pathway research (the well-known daf-2/insulin-IGF signaling work in C. elegans) directly to human dosing decisions is not supported by current human clinical evidence, and no guideline body has endorsed a specific "optimal" IGF-1 number for longevity purposes as of this writing (January 2025).

Given the U-shaped pattern, a defensible, cautious framing, not a proven optimum, is to avoid both ends of the range: avoid values persistently below the age-adjusted normal range, and avoid sustained values well above it. Where this page's "AtAGlance" box gives a numeric target of roughly 150 to 250 ng/mL for adults 30 to 60, that is a plausible, commonly discussed heuristic derived from staying in the upper-middle of the age-adjusted range, not an established clinical target with its own outcome trial.

What throws off the reading and mimics a real change?

Several variables can move IGF-1 with no change in GH axis activity or peptide dose. These should be screened before a dose is adjusted.

Nutritional status. IGF-1 is a sensitive nutritional marker; protein restriction can lower it within about a week regardless of GH secretion (Rosenfeld & Hwa, 2009). A patient starting a calorie deficit at the same time as a peptide may show a flat or falling IGF-1 despite the peptide working pharmacologically.

Insulin resistance and liver function. IGF-1 is produced almost entirely in the liver downstream of GH receptor signaling. Conditions that impair hepatic GH receptor signaling, including non-alcoholic fatty liver disease and insulin resistance, can blunt IGF-1 output even when GH secretion itself is normal or high (Rosenfeld & Hwa, 2009).

Thyroid function. Hypothyroidism reduces GH receptor sensitivity and can slow IGF-1 synthesis. An undiagnosed elevated TSH can flatten an expected rate of change on a peptide protocol, which is why TSH is worth checking alongside IGF-1 when the response looks weaker than expected.

Timing of the draw. GH is secreted in nocturnal pulses, and IGF-1's longer half-life buffers short-term GH swings, making it more stable across the day than GH itself. Fasting morning draws still standardize the comparison and reduce postprandial GH suppression effects on the reading.

When does a rising IGF-1 become a safety concern?

The Endocrine Society's guideline for adult GH deficiency states that IGF-1 should be kept within the normal range for age and sex during GH replacement, and that persistent elevation above the upper limit should prompt dose reduction (Molitch et al., 2011). That is a guideline recommendation for an FDA-approved indication. For off-label GH secretagogue peptides, the same principle is applied by clinical judgment and analogy, not by direct guideline coverage, since these peptides are not FDA-approved for this use and have not been through the same regulatory review.

A practical, cautious threshold some clinicians use is an IGF-1 persistently above roughly 300 ng/mL in adults over 40, confirmed on two draws about 4 weeks apart, as a trigger for dose reduction or a therapy hold. A rise of more than roughly 100 ng/mL within 8 weeks is a rate-of-change flag independent of the absolute value, because steep trajectories raise the odds of overshooting the intended range before the next scheduled draw.

Acromegaly is a different thing. Active acromegaly, from a GH-secreting pituitary adenoma, produces autonomous, non-suppressible GH and IGF-1 hypersecretion, with IGF-1 values typically well above the ranges discussed on this page. GH secretagogue peptides act through intact hypothalamic-pituitary feedback loops and remain subject to that feedback, so they do not reproduce the autonomous hypersecretion that defines acromegaly. That said, chronically supraphysiological IGF-1 from any source, including exogenous stimulation, may still contribute to joint discomfort or worsened glucose metabolism in susceptible people, which is a separate concern from acromegaly and still a reason to keep values within range.

When to seek urgent care. New severe headache, visual field changes, rapidly enlarging hands or feet, or signs suggestive of a pituitary mass are not managed by lab monitoring alone and warrant prompt medical evaluation rather than waiting for a scheduled recheck.

A practical monitoring protocol

• Use the same laboratory and assay platform for every draw in a monitoring series.
• Draw fasting (at least 8 hours), in the morning, ideally between 7 and 9 AM.
• Avoid drawing during acute illness, shortly after surgery, or during corticosteroid exposure.
• Record estrogen route and dose for female patients; oral versus transdermal estrogen changes the comparison.
• Record recent protein intake and any significant caloric change.
• Check TSH, fasting glucose, and fasting insulin alongside IGF-1 during titration, since these confounders are inexpensive to screen and easy to miss otherwise.
• Track values over time with dates, doses, and relevant clinical changes noted alongside each result, rather than reviewing any single value in isolation.

What is established, what is plausible, and what is not established

Established: IGF-1 declines with age; assay platform materially affects the reported number; oral estrogen suppresses hepatic IGF-1 relative to transdermal estrogen; guideline bodies recommend recheck intervals of 1 to 2 months after a GH-replacement dose change, then roughly every 6 months once stable, for the FDA-approved indication of adult GH deficiency; both persistently low and persistently high IGF-1 are associated with adverse outcomes in observational data.

Plausible but not proven: applying the same monitoring cadence and rate-of-change thresholds to off-label GH secretagogue peptides used for longevity or body-composition goals; a specific "optimal" numeric target such as 150 to 250 ng/mL for adults 30 to 60; that keeping IGF-1 in the upper-middle of the age-adjusted range, rather than at the population median, meaningfully changes long-term outcomes for a given individual.

Not established: that any specific peptide protocol produces a defined, reproducible per-week IGF-1 slope across patients; that human longevity is causally improved by deliberately lowering IGF-1, an extrapolation from invertebrate models that has not been confirmed in human trials; precise trial-level numbers for sermorelin, MK-677, or body-composition outcomes that could not be independently verified against the primary sources available for this draft. Where this page could not verify a specific number against its cited source, the number has been removed or clearly flagged rather than presented as settled fact.